W. L. Gore & Associates (Gore) announced that the FDA granted approval for the use of GORE HELEX Septal Occluder with a modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD), providing a percutaneous ASD closure solution for very young patients.
The GORE HELEX Septal Occluder is a permanently implanted prosthesis that uses ePTFE, a biocompatible material that allows tissue ingrowth, to seal the defect.
June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...
June 20, 2024 
July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...
July 14, 2023 
May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...
May 05, 2022 
October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...
October 04, 2021 
September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...
September 20, 2021 
April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...
April 20, 2021 
Interview with Carey Kimmelstiel, M.D., FACP, FACC, director, cardiac catheterization laboratory, director ...
March 24, 2020 
June 10, 2019 – W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket ...
June 10, 2019 
March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective ...
March 27, 2019 
February 13, 2019 — Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo ...
February 13, 2019